A detailed history of Erste Asset Management Gmb H transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Erste Asset Management Gmb H holds 23,800 shares of NBIX stock, worth $3.31 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
23,800
Holding current value
$3.31 Million
% of portfolio
0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $2.73 Million - $3.64 Million
23,800 New
23,800 $2.74 Billion
Q2 2022

Nov 26, 2024

SELL
$75.79 - $100.07 $7.36 Million - $9.72 Million
-97,100 Reduced 80.31%
23,800 $2.34 Billion
Q1 2022

Nov 22, 2024

SELL
$72.45 - $94.81 $79,695 - $104,291
-1,100 Reduced 4.42%
23,800 $2.2 Billion
Q4 2021

Nov 22, 2024

BUY
$79.65 - $106.22 $87,615 - $116,842
1,100 Added 4.62%
24,900 $2.1 Billion
Q4 2020

Nov 22, 2024

SELL
$86.91 - $108.33 $1.29 Million - $1.6 Million
-14,800 Reduced 37.28%
24,900 $2.34 Billion
Q3 2020

Nov 22, 2024

BUY
$96.16 - $135.15 $1.53 Million - $2.15 Million
15,900 Added 66.81%
39,700 $3.88 Billion
Q1 2020

Nov 22, 2024

SELL
$75.11 - $113.76 $5.63 Million - $8.53 Million
-75,000 Reduced 65.39%
39,700 $3.64 Billion
Q4 2019

Nov 22, 2024

BUY
$86.8 - $118.57 $7.89 Million - $10.8 Million
90,900 Added 381.93%
114,700 $12.3 Billion
Q3 2019

Nov 22, 2024

SELL
$83.82 - $101.5 $670,560 - $812,000
-8,000 Reduced 7.64%
96,700 $8.72 Billion
Q2 2019

Nov 22, 2024

SELL
$72.24 - $91.27 $72,240 - $91,270
-1,000 Reduced 0.95%
104,700 $8.76 Billion
Q1 2019

Nov 22, 2024

BUY
$69.31 - $91.53 $5.68 Million - $7.5 Million
81,900 Added 344.12%
105,700 $9.21 Billion
Q4 2018

Nov 26, 2024

BUY
$68.32 - $124.36 $6.63 Million - $12.1 Million
97,100 Added 407.98%
120,900 $8.44 Billion

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.3B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.